Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing.
Loison G, Bouges Le Royer H, Marsili S, Brice A, Vintejoux J, Yakoubi M, Sirgue H, Chatelut E, Etienne-Grimaldi MC, Thomas F; on behalf of the GPCO-UNICANCER group. Loison G, et al. Among authors: etienne grimaldi mc. Clin Chem Lab Med. 2024 Jan 11;62(6):e129-e131. doi: 10.1515/cclm-2023-1096. Print 2024 May 27. Clin Chem Lab Med. 2024. PMID: 38198224 Free article. No abstract available.
A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E. Schmitt A, et al. Clin Cancer Res. 2009 May 15;15(10):3633-9. doi: 10.1158/1078-0432.CCR-09-0017. Epub 2009 Apr 28. Clin Cancer Res. 2009. PMID: 19401344 Clinical Trial.
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Mousseau M, Pinguet F, Floquet A, Billaud EM, Durdux C, Le Guellec C, Mazières J, Lafont T, Ollivier F, Concordet D, Chatelut E. Schmitt A, et al. J Clin Oncol. 2010 Oct 20;28(30):4568-74. doi: 10.1200/JCO.2010.29.3597. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855828
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.
Etienne-Grimaldi MC, Bennouna J, Formento JL, Douillard JY, Francoual M, Hennebelle I, Chatelut E, Francois E, Faroux R, El Hannani C, Jacob JH, Milano G. Etienne-Grimaldi MC, et al. Br J Clin Pharmacol. 2012 May;73(5):776-85. doi: 10.1111/j.1365-2125.2011.04141.x. Br J Clin Pharmacol. 2012. PMID: 22486600 Free PMC article. Clinical Trial.
New advances in DPYD genotype and risk of severe toxicity under capecitabine.
Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G. Etienne-Grimaldi MC, et al. PLoS One. 2017 May 8;12(5):e0175998. doi: 10.1371/journal.pone.0175998. eCollection 2017. PLoS One. 2017. PMID: 28481884 Free PMC article.
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.
Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, Loriot MA, Paci A, Royer B, Thomas F, Ciccolini J. Etienne-Grimaldi MC, et al. Semin Oncol. 2017 Apr;44(2):159-160. doi: 10.1053/j.seminoncol.2017.06.001. Epub 2017 Jul 4. Semin Oncol. 2017. PMID: 28923215 No abstract available.
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC. Loriot MA, et al. Bull Cancer. 2018 Apr;105(4):397-407. doi: 10.1016/j.bulcan.2018.02.001. Epub 2018 Feb 24. Bull Cancer. 2018. PMID: 29486921 Free article. Review. French.
86 results